Biogen | BIIB - Sales Revenues

Stock Price
179.03
Daily Change
-0.86 -0.48%
Monthly
1.73%
Yearly
24.39%
Q1 Forecast
174.35

Biogen reported $2.53B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 15.78B 360M Sep/2025
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Amgen USD 9.56B 380M Sep/2025
Bayer EUR 9.66B 1.08B Sep/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.2B 70M Sep/2025
Eli Lilly USD 17.6B 2.04B Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Merck USD 17.28B 1.47B Sep/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Pfizer USD 16.7B 2B Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sanofi EUR 12.2B 3.19B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025